BDR Pharma to launch 400mg Favipiravir tablets at Rs 990 for 10 tablets


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ BDR Pharma to launch 400mg Favipiravir tablets at Rs 990 for 10 tablets
After 200 mg favipiravir tablets BDR to launch 400 mg Favipiravir tablets under brand name BDFAVI

Drug firm BDR Pharmaceuticals on Friday said it plans to launch 400 mg Favipiravir tablets, used for treating COVID-19 patients, in the country. The ‘BDFAVI’ 400 mg tablets will be priced at Rs 990 for a strip of 10 tablets, BDR Pharma said in a statement. Each tablet will cost Rs 99.

In August, the company launched 200 mg Favipiravir tablets. “We aim to make BDFAVI available in sufficient quantities to meet the high demand for the drug in the Indian market to help curb the current crisis… introducing a higher dosage is an attempt to ensure a smoother experience to patients and caregivers,” BDR PharmaCMD Dharmesh Shah said.


The companyhad received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild to moderate COVID-19 symptoms under the brand name BDFAVI, according to the statement.

BDR Group of companies has grown steadily and become a house-hold name in the pharmaceutical Industry over the last 15 years, in both domestic and international arenas. They are recognized as a “niche” player in manufacturing of Pharmaceutical APIs and for our renowned new age formulations. The group is complemented majorly by its two companies - BDR Pharmaceuticals International Pvt Ltd and BDR Life sciences Pvt. Ltd, each one having stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively.

BDR Group focuses on development in 4 specialized therapeutic segments, viz. Oncology, Critical care, Gynecology & Neurology, which are its dream segments.

Over the years, BDR has built an undeniable reputation for its specialization in early identification, development and introduction of new molecules, in a continuous endeavor to make globally available high cost medicines to local masses at affordable prices;

Innovation and development are the inalienable cornerstones of BDR group. Investing heavily in R&D activities, possess state–of-the-art API and Formulation development centers accredited by the DSIR, Government of India. Our facilities are in a state of constant & continuous upgradation, so as to keep up and meet with the constantly growing demands of the dynamic International scenario. Blending of human skill and innovative expertise of BDR often acts as a catalyst for development of desired modern technology and setting up of world class facilities.

BDR‘s philosophy of sustained growth and consolidation is achieved by strategic tie-ups with several globally renowned players. Today, we can boast of having tie-ups with market leaders in almost all the strategically important emerging markets. We are proud recipient of “Golden Award for Best Exporter” from Pharmexcil (Export Promotion Council) consecutively since 2010.

Tags : #BDPharma #BDFavi #200mgBDFAVI #400mgBDFavi #Favipiravir400mgPrice #LatestPharmaNewsUpdateSep7 #IndiaPharmaNewsUpdate #NewFavipiravirBDFavi #Oncology

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026